tetano
Editor, Senior Moderator
J Infect Public Health
. 2023 May 17;16(8):1184-1192.
doi: 10.1016/j.jiph.2023.05.017. Online ahead of print. Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study
Gleyce Hellen de Almeida de Souza[SUP] 1 [/SUP], Alexandre Ribeiro de Oliveira[SUP] 1 [/SUP], Marcelo Dos Santos Barbosa[SUP] 1 [/SUP], Luana Rossato[SUP] 1 [/SUP], Kerly da Silva Barbosa[SUP] 2 [/SUP], Simone Simionatto[SUP] 3 [/SUP]
Affiliations
Epidemiological data regarding the incidence of secondary multidrug-resistant (MDR) Gram-negative infection in patients with coronavirus disease (COVID-19) in Brazil are still ambiguous. Thus, a case-control study was designed to determine factors associated with the acquisition of MDR Gram-negative bacteria (GNB) in patients with and without COVID-19 and describe the mortality rates and clinical features associated with unfavorable outcomes. In total, we assessed 280 patients admitted to Brazilian intensive care units from March/2020 to December/2021. During the study, 926 GNB were isolated. Out of those, 504 were MDR-GNB, representing 54.4% of the resistance rate. In addition, out of 871 patients positive for COVID-19, 73 had secondary MDR-GNB infection, which represented 8.38% of documented community-acquired GNB-MDR infections. The factors associated with patients COVID-19-MDR-GNB infections were obesity, heart failure, use of mechanical ventilation, urinary catheter, and previous use of β-lactams. Several factors associated with mortality were identified among patients with COVID-19 infected with MDR-GNB, including the use of a urinary catheter; renal failure; and the origin of bacterial cultures such as tracheal secretion, exposure to carbapenem antibiotics, and polymyxin. Mortality was significantly higher in patients with COVID-19-MDR-GNB (68.6%) compared to control groups, where COVID-19 was 35.7%, MDR-GNB was 50%, and GNB was 21.4%. Our findings demonstrate that MDR-GNB infection associated with COVID-19 has an expressive impact on increasing the case fatality rate, reinforcing the importance of minimizing the use of invasive devices and prior exposure to antimicrobials to control the bacterial spread in healthcare environments to improve the prognosis among critical patients.
Keywords: Antimicrobial resistance; Healthcare-associated infections; Multi-drug resistance; Public health; SARS-CoV-2.
. 2023 May 17;16(8):1184-1192.
doi: 10.1016/j.jiph.2023.05.017. Online ahead of print. Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study
Gleyce Hellen de Almeida de Souza[SUP] 1 [/SUP], Alexandre Ribeiro de Oliveira[SUP] 1 [/SUP], Marcelo Dos Santos Barbosa[SUP] 1 [/SUP], Luana Rossato[SUP] 1 [/SUP], Kerly da Silva Barbosa[SUP] 2 [/SUP], Simone Simionatto[SUP] 3 [/SUP]
Affiliations
- PMID: 37271099
- DOI: 10.1016/j.jiph.2023.05.017
Epidemiological data regarding the incidence of secondary multidrug-resistant (MDR) Gram-negative infection in patients with coronavirus disease (COVID-19) in Brazil are still ambiguous. Thus, a case-control study was designed to determine factors associated with the acquisition of MDR Gram-negative bacteria (GNB) in patients with and without COVID-19 and describe the mortality rates and clinical features associated with unfavorable outcomes. In total, we assessed 280 patients admitted to Brazilian intensive care units from March/2020 to December/2021. During the study, 926 GNB were isolated. Out of those, 504 were MDR-GNB, representing 54.4% of the resistance rate. In addition, out of 871 patients positive for COVID-19, 73 had secondary MDR-GNB infection, which represented 8.38% of documented community-acquired GNB-MDR infections. The factors associated with patients COVID-19-MDR-GNB infections were obesity, heart failure, use of mechanical ventilation, urinary catheter, and previous use of β-lactams. Several factors associated with mortality were identified among patients with COVID-19 infected with MDR-GNB, including the use of a urinary catheter; renal failure; and the origin of bacterial cultures such as tracheal secretion, exposure to carbapenem antibiotics, and polymyxin. Mortality was significantly higher in patients with COVID-19-MDR-GNB (68.6%) compared to control groups, where COVID-19 was 35.7%, MDR-GNB was 50%, and GNB was 21.4%. Our findings demonstrate that MDR-GNB infection associated with COVID-19 has an expressive impact on increasing the case fatality rate, reinforcing the importance of minimizing the use of invasive devices and prior exposure to antimicrobials to control the bacterial spread in healthcare environments to improve the prognosis among critical patients.
Keywords: Antimicrobial resistance; Healthcare-associated infections; Multi-drug resistance; Public health; SARS-CoV-2.